Results 91 to 100 of about 56,599 (248)

Tumor Necrosis Factor-Alpha Targeting Can Protect against Arthritis with Low Sensitization to Infection

Frontiers in Immunology, 2017
Tumor necrosis factor-alpha (TNF-α) blockade is an effective treatment for rheumatoid arthritis (RA) and other inflammatory diseases, but in patients, it is associated with reduced resistance to the infectious agents Mycobacterium tuberculosis and ...
Nadia Belmellat, Nadia Belmellat, Luca Semerano, Luca Semerano, Luca Semerano, Noria Segueni, Diane Damotte, Patrice Decker, Patrice Decker, Bernhard Ryffel, Bernhard Ryffel, Valérie Quesniaux, Marie-Christophe Boissier, Marie-Christophe Boissier, Marie-Christophe Boissier, Eric Assier, Eric Assier   +16 more
doaj   +1 more source

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang, Umar Raza, Jia Song, Junyan Lu, Shun Yao, Xiaohong Liu, Wei Zhang, Shujuan Li   +7 more
wiley   +1 more source

Scleritis: A Paradoxical Effect of Etanercept? Etanercept-associated Inflammatory Eye Disease

, 2011
Objective.To describe 3 cases of scleritis associated with etanercept use for rheumatoid arthritis (RA) and to review the literature related to inflammatory eye diseases associated with the use of etanercept.Methods.Three cases of severe scleritis during
FRÉDÉRIC LIOTÉ, CLÉMENT PRATI, CECILIA GIAMPIETRO, HANG-KORNG EA, DANIEL WENDLING, THOMAS GAUJOUX, CÉCILE GAUJOUX-VIALA, PHILIPPE ORCEL   +7 more
core   +1 more source

Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study

BMC Musculoskeletal Disorders, 2004
Background Variability in dosing and costs of biologics among patients with rheumatoid arthritis (RA) is of interest to healthcare descision-makers.
Smith Daniel, Gilbert Thomas D, Ollendorf Daniel A   +2 more
doaj  

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler, Friederike Zimmermann, Bettina Heidecker, Ulf Landmesser, Arash Haghikia   +4 more
wiley   +1 more source

Predictors of the response to etanercept in patients with juvenile idiopathic arthritis without systemic manifestations within 12 months: results of an open-label, prospective study conducted at the National Scientific and Practical Center of Children's Health, Russia

Pediatric Rheumatology Online Journal, 2017
Background The aim of this study was to investigate the efficacy of etanercept treatment and to identify predictors of response to therapy within 12 months in patients with juvenile idiopathic arthritis (JIA) without systemic manifestations.
Ekaterina I. Alexeeva, Leyla S. Namazova-Baranova, Tatyana M. Bzarova, Saniya I. Valieva, Rina V. Denisova, Tatyana V. Sleptsova, Kseniya B. Isaeva, Alexandra M. Chomahidze, Nikolay I. Taibulatov, Anna N. Fetisova, Anna V. Karaseva, Alexandr A. Baranov   +11 more
doaj   +1 more source

Adverse drug events of etanercept.

, 2018
Adverse drug events of etanercept.
Soo An Choi (769572), Jeong Yun Choi (5949605), Jee Eun Chung (5949608), Yoon Sook Cho (5949611), Ji Hyun Park (1541242), Yong Woo Jung (234356)   +5 more
core   +1 more source

Concomitant Treatment with Etanercept and Tacrolimus Synergistically Attenuates Arthritis Progression via Inhibition of Matrix Metalloproteinase-3 Production and Osteoclastogenesis in Human TNF-α Transgenic Mice

Mediators of Inflammation, 2019
In the present study, we investigated the effects and mechanisms of action of a combined treatment with etanercept, a soluble tumor necrosis factor receptor (p75) Fc fusion protein, and tacrolimus, a calcineurin inhibitor on the progression of arthritis ...
Iwao Seki, Miwa Takai-Imamura, Tomomi Kohara-Tanaka, Satoshi Shirae, Minoru Sasano, Hiroaki Matsuno, Hiroyuki Aono   +6 more
doaj   +1 more source

JAK Inhibitors in Psoriatic–Atopic Dermatitis Overlap: A Four‑Case Series

JEADV Clinical Practice, EarlyView.
ABSTRACT Overlap between psoriasis and atopic dermatitis (AD) poses diagnostic and therapeutic challenges; monoclonal antibodies targeting a single axis may improve one component while worsening the other [1]. Janus kinase (JAK) inhibitors act pleiotropically and may provide simultaneous control of psoriatic and eczematous inflammation [2].
Eleonora Bongiovanni, Francois Rosset, Isotta Giunipero di Corteranzo, Lorenzo Bellando, Rebecca Senetta, Simone Ribero, Pietro Quaglino   +6 more
wiley   +1 more source

Safety of etanercept in elderly subjects with rheumatoid arthritis

, 2009
Alfredomaria Lurati, Mariagrazia Marrazza, Katia Angela, Magda ScarpelliniFornaroli Hospital, Rheumatology Unit, Magenta, ItalyObjective: To report side effects seen in a clinical cohort of patients aged >65 years with rheumatoid arthritis (RA ...
Mariagrazia Marrazza, Katia Angela, Alfredomaria Lurati, et al   +3 more
core